ATRA übertreffen die 19 der letzten 40Schätzungen.
48%
Nächster Bericht
Datum des nächsten Berichts
05. März 2026
Estimate forQ4 25(Revenue/ EPS)
$2.72M
/
-$0.44
Implizierte Änderung vonQ3 25(Revenue/ EPS)
-21.09%
/
+37.50%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
-91.68%
/
-63.03%
Atara Biotherapeutics, Inc earnings per share and revenue
On 12. Nov. 2025, ATRA reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.87 USD, resulting in a 63.52% surprise. Revenue reached 3.45 million, compared to an expected 1.43 million, with a 142.21% difference. The market reacted with a -0.72% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.44 USD, with revenue projected to reach 2.72 million USD, implying an increase of 37.50% EPS, and decrease of -21.09% in Revenue from the last quarter.
FAQ
What were Atara Biotherapeutics, Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Atara Biotherapeutics, Inc reported EPS of -$0.32, beating estimates by 63.52%, and revenue of $3.45M, 142.21% above expectations.
How did the market react to Atara Biotherapeutics, Inc's Q3 2025 earnings?
The stock price moved down -0.72%, changed from $12.56 before the earnings release to $12.47 the day after.
When is Atara Biotherapeutics, Inc expected to report next?
The next earning report is scheduled for 05. März 2026.
What are the forecasts for Atara Biotherapeutics, Inc's next earnings report?
Based on 6
analysts, Atara Biotherapeutics, Inc is expected to report EPS of -$0.44 and revenue of $2.72M for Q4 2025.